CD274 and non-small cell lung carcinoma: Despite the lack of clinical evidence in NSCLC patients, local RFA has been shown to increase PD‐L1 expression in distant tumors in a variety of cancers, suggesting that patients with tumors lacking PD‐L1 receptors may benefit from immunotherapy.74, 75